New drug EDK060 enters first human tests for nerve disease CMT1A
NCT ID NCT07140614
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This early-stage trial tests a new drug called EDK060 in 28 adults with Charcot-Marie-Tooth type 1A, a genetic nerve disorder. Participants receive a single dose of EDK060 or a placebo to check safety and how the drug moves through the body. The goal is to see if EDK060 is safe enough for further study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EDK060
- What this could lead to
- If safe, this could pave the way for a treatment that slows or controls CMT1A progression.
- What could go wrong
- This is a very early Phase 1 trial with only 28 people, focused on safety, not effectiveness. It may not lead to a working treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHARCOT-MARIE-TOOTH DISEASE TYPE 1A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CIUSS de l´Estrie-CHUS- Hôpital Fleurimont
RECRUITINGSherbrooke, Quebec, J1H 5N4, Canada
-
Montreal Neurological Institute
RECRUITINGMontreal, Quebec, H3A 2B4, Canada
-
Novartis Investigative Site
RECRUITINGMontreal, Quebec, H2X 1R9, Canada
-
The Ottawa Hospital
RECRUITINGOttawa, Ontario, K1H 8L6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.